Hikma Pharmaceuticals reiterated full-year guidance as the company reported solid trading across its business.
The FTSE 250 group said its injectables division was performing well with the US on track for growth in the year to the end of December. In Europe Hikma’s own products are selling strongly and the company is carrying out contract manufacturing.

Hikma said its generics business is continuing the strong performance of the first half. Annual generics revenue will be $810m-$830m and the core operating margin will be at the top of guidance for 22-24%, the company said. Branded products are selling well, in line with expectations.

Siggi Olafsson, Hikma’s chief executive, said: “Our business continues to perform strongly, enabling us to reiterate our full year guidance to achieve another year of growth. While the global pandemic continues to bring some volatility, we are leveraging our resilient commercial and operational capabilities to drive growth and to reliably deliver medicines to our customers and patients.”

Injectables revenue will increase by mid-single digits and the division’s core operating margin will be in the range of 37% to 38%, Hikma said. Branded revenue growth in constant currency will be in the mid-single digits, it added.

Hikma shares rose 0.2% to £24.69 at 08:21 GMT.

Related articles

Ryanair passenger numbers jump 9% in December

Ryanair passenger numbers jump 9% in December

(Sharecast News) - Budget airline Ryanair reported a 9% jump in December passenger numbers on Wednesday. Traffic rose to 12.54 million from 11.52m in the same month a year earlier, while the load factor - which gauges how full the planes are - ticked down to 91% from...

Wizz Are passenger numbers soar in December

Wizz Are passenger numbers soar in December

(Sharecast News) - Hungary-based budget airline Wizz Air reported a strong rise in December passenger numbers as demand continued to rebound from the Covid pandemic. The company on Wednesday said it carried 4,964,857 passengers, an 18.8% increase year on year. For the...

Trending stories

Join our mailing list

Subscribe to our mailing list to receive regular updates!

x